SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 2,038.07 |
| Enterprise Value ($M) | 1,928.11 |
| Book Value ($M) | 394.97 |
| Book Value / Share | 6.46 |
| Price / Book | 5.16 |
| NCAV ($M) | 224.53 |
| NCAV / Share | 3.66 |
| Price / NCAV | 9.08 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.31 |
| Return on Assets (ROA) | -0.24 |
| Return on Equity (ROE) | -0.32 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.73 |
| Current Ratio | 4.73 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 405.32 |
| Assets | 575.76 |
| Liabilities | 180.79 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 78.59 |
| Operating Income | -165.53 |
| Net Income | -146.96 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -102.83 |
| Cash from Investing | 139.89 |
| Cash from Financing | 4.19 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D | Baker Bros. Advisors Lp | 9.80 | 0.03 | |
| 13G/A | Avoro Capital Advisors LLC | 6.80 | -1.95 | |
| 13G/A | Vanguard Group Inc | 6.73 | 9.21 | |
| 13G/A | Price T Rowe Associates Inc /md/ | 10.10 | 37.00 | |
| 13G/A | Atlas Venture Fund X, L.P. | 8.40 | -1.95 | |
| 13G/A | Wellington Management Group Llp | 8.68 | 4.89 | |
| 13G/A | BlackRock Inc. | 6.40 | 6.95 | |
| 13G/A | State Street Corp | 3.41 | -33.45 | |
| 13D/A | Biotechnology Value Fund L P | 9.99 | 24.26 | |
| 13D/A | Vertex Pharmaceuticals Inc / Ma | 0.00 | -100.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 71,270 | 243,392 | 29.28 | |
| 197,286 | 323,221 | 61.04 | |
| 89,960 | 153,382 | 58.65 | |
| 122,499 | 176,234 | 69.51 | |
| 88,005 | 213,650 | 41.19 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| KALV – KalVista Pharmaceuticals, Inc. | KOD – Kodiak Sciences Inc. |
| KROS – Keros Therapeutics, Inc. | LBPH – Longboard Pharmaceuticals, Inc. |
| LGND – Ligand Pharmaceuticals Incorporated |
Financial data and stock pages provided by
Fintel.io